The Indian embassy in Iran recently celebrated the arrival of 1.0 million doses of Covaxin, a COVID vaccine developed in India by the pharmaceutical company Bharat Biotech. What’s allowed India to get here so quickly, having been in such a bad position earlier this year, is its huge increase in COVID vaccine production. Although having now resumed, India’s vaccine exports won’t gain significant momentum until next year, according to recent statements. The delay in regulatory approval for the COVID vaccine developed by Novavax, which the institute is also manufacturing, is an additional factor here. High-income countries have also pledged to share close to 2.0 billion vaccine doses with lower-income countries, but so far, only 14 per cent of these donations have been sent.

Source: bd News24 October 23, 2021 08:38 UTC